LL-37 is a naturally occurring antimicrobial peptide derived from human cathelicidin, playing a key role in innate immunity. It is widely studied for its ability to kill bacteria, viruses, and fungi by disrupting their cell membranes. Due to this property, LL-37 is being explored for use in treating infected wounds, especially chronic ulcers like diabetic foot ulcers, where standard antibiotics may fail.

It promotes wound healing by stimulating cell migration and proliferation, and by encouraging the formation of new blood vessels (angiogenesis). This makes it valuable in regenerative medicine and dermatology.

LL-37 also shows immunomodulatory effects—it can reduce excessive inflammation, making it relevant in conditions like psoriasis or inflammatory bowel disease. Researchers are investigating its potential in developing new anti-infective coatings for medical devices, such as catheters or implants, to prevent biofilm formation.

In cancer research, LL-37 has dual roles: it may support tumor growth in some contexts, while in others, it shows anti-tumor activity. This complex behavior is under active study to determine its role in cancer progression and therapy.

Overall, LL-37 holds promise as a template for designing new peptide-based drugs with broad-spectrum activity and low risk of inducing microbial resistance.